Welcome to our dedicated page for NextTrip SEC filings (Ticker: NTRP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NextTrip鈥檚 filings tell a unique story鈥攐ne that blends a high-velocity travel booking engine with a fast-growing media network that turns vacation inspiration into revenue. Investors hunting for the crossover between tourism and digital media will find it here, line by line, in every 10-K and 10-Q.
Stock Titan鈥檚 AI steps in where dense disclosure begins. Our platform offers AI-powered summaries that transform a 300-page 鈥淣extTrip annual report 10-K simplified鈥� into a five-minute read. Need the latest 鈥淣extTrip quarterly earnings report 10-Q filing鈥� or a quick look at 鈥淣extTrip 8-K material events explained鈥�? They appear in real time the moment EDGAR releases them.
Wondering how influencers, advertising sales, and bundled resort packages shape margins? The Management鈥檚 Discussion is tagged so you can jump straight to segment revenue. Curious about leadership moves? 鈥淣extTrip insider trading Form 4 transactions鈥� and 鈥淣extTrip executive stock transactions Form 4鈥� are streamed with alert options, giving you 鈥淣extTrip Form 4 insider transactions real-time鈥� insight before markets react.
- Compare booking vs. media growth with our 鈥淣extTrip earnings report filing analysis鈥� module.
- Review 鈥淣extTrip proxy statement executive compensation鈥� to see how bonuses align with content-to-commerce KPIs.
- Use SmartSearch to answer 鈥渦nderstanding NextTrip SEC documents with AI鈥� in seconds.
From risk factors on Caribbean seasonality to revenue recognition for white-label widgets, every filing is explained simply and updated instantly. No more eye-straining PDFs鈥攋ust the disclosures that drive decisions.
On 29 Jul 2025, Akari Therapeutics plc (AKTX) filed a Form S-8 to register additional securities for employee compensation plans. The filing covers (i) 18,826,000,000 ordinary shares (鈮� 9.413 million ADSs) reserved for future grants under the Akari 2023 Equity Incentive Plan and (ii) 1,922,625,000 ordinary shares (鈮� 0.961 million ADSs) tied to options issued under the Peak Bio 2022 Long-Term Incentive Plan that Akari assumed as part of the March 2024 merger with Peak Bio.
The company is classified as a non-accelerated, smaller reporting company. Except for the newly registered shares, Akari incorporates by reference its prior S-8 (File No. 333-274954) and recent Exchange Act filings, so no new financial statements are presented. Standard undertakings, indemnification language and a list of opinion and consent exhibits are included. While the registration itself does not raise capital, issuance of these shares upon exercise or vesting could increase the share count and dilute existing holders; conversely, the enlarged equity pool supports employee retention and post-merger integration.
Crown Holdings (CCK) reported Q2-25 results that showed moderate top-line growth and sharply higher profitability. Net sales rose 3.6% YoY to $3.15 bn and operating income improved 3.2% to $391 m despite $47 m of restructuring/other charges. Net income attributable to Crown increased 4% to $181 m; diluted EPS expanded 7.6% to $1.56 on a 3% lower share count following $209 m of buybacks.
First-half trends were stronger. Six-month revenue grew 3.6% to $6.04 bn while EPS jumped 59% to $3.21, aided by lower interest expense (-10%) and higher segment income (+11%). Operating cash flow reached $463 m (+35%), easily covering reduced capex of $89 m and funding dividends ($60 m) and repurchases.
Balance-sheet quality improved. Long-term debt fell $440 m to $5.62 bn after redeeming $875 m of 4.75% notes (partly replaced with a new $700 m 5.875% 2033 issue). Net leverage benefits from higher cash ($936 m) and stronger EBITDA. However, current maturities surged to $671 m as 2026 notes move inside twelve months.
Notable items. 鈥� $11 m asbestos reserve tied to an adverse California verdict; total asbestos accrual now $189 m. 鈥� FX translation gains lifted OCI but net investment hedge losses of $98 m offset. 鈥� Segment income rose in Americas and Europe but slipped in Asia-Pacific. 鈥� Supplier-finance obligations stay high at $883 m.
Outlook. Management continues to emphasize long-term beverage-can demand growth, disciplined capex, debt pay-down and the $2.0 bn buyback authorization through 2027.
Franklin Financial Services (FRAF) 鈥� Insider transaction summary
EVP/CFO Mark R. Hollar filed a Form 4 for transactions on 07/25/2025:
- Option exercise (Code M): 3,000 common shares acquired at a strike price of $30.00.
- Share withholding (Code F): 2,102 shares surrendered at the market price of $42.83 to fund the cashless exercise.
After the two entries, Hollar鈥檚 direct beneficial ownership stands at 15,572 shares (plus 96 DRIP shares and previously reported unvested RSUs). The net result is an increase of 鈮�898 shares, signalling a modest rise in insider exposure. No derivative securities remain from the 2017 option grant; 2,927 options from a 2018 grant are still outstanding.
Insider option exercises when the market price materially exceeds the strike (鈻� 43%) can indicate executive confidence and are generally viewed positively, although the partial share disposition tempers the signal. The transaction does not impact earnings or guidance but may be of interest to investors tracking insider sentiment.
Form 3 filing for NextTrip, Inc. (NTRP) discloses that newly reported director Andrew Jay Kaplan indirectly owns 75,000 shares of the company鈥檚 common stock through KC Global Media Asia, LLC. Kaplan is deemed a beneficial owner because he is Chairman of KCGM, but he disclaims ownership beyond his pecuniary interest. No derivative securities are reported. The filing is an initial Section 16(a) statement and does not amend any prior filing.
Form 4 鈥� Insider Option Grant
On 06/25/2025, Director Jacob Brunsberg received a stock option covering 50,000 shares of NextTrip, Inc. (NTRP) at an exercise price of $3.37. The award (transaction code 鈥淎鈥�) vests immediately and expires on 06/24/2027. After the transaction, Brunsberg holds 50,000 derivative securities and reported no changes in direct common-stock ownership.
The filing provides a new equity incentive for the director while introducing potential dilution of up to 50,000 shares if the options are exercised.
Form 4 鈥� Insider Option Grant
On 06/25/2025, Director Jacob Brunsberg received a stock option covering 50,000 shares of NextTrip, Inc. (NTRP) at an exercise price of $3.37. The award (transaction code 鈥淎鈥�) vests immediately and expires on 06/24/2027. After the transaction, Brunsberg holds 50,000 derivative securities and reported no changes in direct common-stock ownership.
The filing provides a new equity incentive for the director while introducing potential dilution of up to 50,000 shares if the options are exercised.
Form 4 鈥� Insider Option Grant
On 06/25/2025, Director Jacob Brunsberg received a stock option covering 50,000 shares of NextTrip, Inc. (NTRP) at an exercise price of $3.37. The award (transaction code 鈥淎鈥�) vests immediately and expires on 06/24/2027. After the transaction, Brunsberg holds 50,000 derivative securities and reported no changes in direct common-stock ownership.
The filing provides a new equity incentive for the director while introducing potential dilution of up to 50,000 shares if the options are exercised.
Form 4 鈥� Insider Option Grant
On 06/25/2025, Director Jacob Brunsberg received a stock option covering 50,000 shares of NextTrip, Inc. (NTRP) at an exercise price of $3.37. The award (transaction code 鈥淎鈥�) vests immediately and expires on 06/24/2027. After the transaction, Brunsberg holds 50,000 derivative securities and reported no changes in direct common-stock ownership.
The filing provides a new equity incentive for the director while introducing potential dilution of up to 50,000 shares if the options are exercised.
Form 4 鈥� Insider Option Grant
On 06/25/2025, Director Jacob Brunsberg received a stock option covering 50,000 shares of NextTrip, Inc. (NTRP) at an exercise price of $3.37. The award (transaction code 鈥淎鈥�) vests immediately and expires on 06/24/2027. After the transaction, Brunsberg holds 50,000 derivative securities and reported no changes in direct common-stock ownership.
The filing provides a new equity incentive for the director while introducing potential dilution of up to 50,000 shares if the options are exercised.
FAQ
What is the current stock price of NextTrip (NTRP)?
What is the market cap of NextTrip (NTRP)?
What is NextTrip's core business model?
How does NextTrip integrate travel media with booking technology?
Who are the primary customers of NextTrip?
How does NextTrip utilize AI in its services?
What differentiates NextTrip from traditional travel agencies?
How do content and commerce converge on NextTrip鈥檚 platform?
What revenue streams does NextTrip have?
How does NextTrip maintain a competitive edge in the travel industry?
